Biomarker of Neuroinflammation in Parkinson’s Disease

• Published in: International journal of molecular sciences Vol. 23; no. 8; p. 4148
• Main Authors: Liu, Tsai-Wei, Chen, Chiung-Mei, Chang, Kuo-Hsuan
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 08.04.2022; MDPI
• Subjects: Animals; Anti-Inflammatory Agents - pharmacology; Antidepressants; Biomarkers; Biomarkers - metabolism; C-reactive protein; Disease Models, Animal; Dopaminergic Neurons - metabolism; Humans; Kinases; Mice; Mice, Inbred C57BL; Microglia - metabolism; Neurodegeneration; Neuroinflammatory Diseases; NLR Family, Pyrin Domain-Containing 3 Protein - metabolism; Parkinson Disease - metabolism; Parkinson's disease; Review; Tumor necrosis factor (TNF)-α; high-sensitivity c-reactive protein (hsCRP); normal T cell expressed and presumably secreted (RANTES); inflammation; IL-2; biomarker; microglia; IL-10; IL-6; Parkinson’s disease; interleukin (IL)-1β
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms23084148

Parkinson’s disease (PD) is caused by abnormal accumulation of α-synuclein in dopaminergic neurons of the substantia nigra, which subsequently causes motor symptoms. Neuroinflammation plays a vital role in the pathogenesis of neurodegeneration in PD. This neuroinflammatory neurodegeneration involves the activation of microglia, upregulation of proinflammatory factors, and gut microbiota. In this review, we summarized the recent findings on detection of PD by using inflammatory biomarkers, such as interleukin (IL)-1β, IL-2, IL-6, IL-10, tumor necrosis factor (TNF)-α; regulated upon activation, normal T cell expressed and presumably secreted (RANTES) and high-sensitivity c-reactive protein (hsCRP); and radiotracers such as [11C]PK11195 and [18F]-FEPPA, as well as by monitoring disease progression and the treatment response. Many PD-causing mutations in SNCA, LRRK2, PRKN, PINK1, and DJ-1 are also associated with neuroinflammation. Several anti-inflammatory medications, including nonsteroidal anti-inflammatory drugs (NSAID), inhibitors of TNF-α and NLR family pyrin domain containing 3 (NLRP3), agonists of nuclear factor erythroid 2-related factor 2 (NRF2), peroxisome proliferator-activated receptor gamma (PPAR-γ), and steroids, have demonstrated neuroprotective effects in in vivo or in vitro PD models. Clinical trials applying objective biomarkers are required to investigate the therapeutic potential of anti-inflammatory medications for PD.